Home
|
About IAC
|
Contact
|
A-Z Index
|
Donate
|
Shop
|
SUBSCRIBE
Immunization Action Coalition
IAC Home
|
News & Information
|
Vaccine News
|
Anthrax

Vaccine News

Anthrax

 Anthrax
 Chickenpox (varicella)
 Diphtheria
 Hepatitis A
 Hepatitis B
 H. influenzae type b
 HPV
 Influenza
 Measles
 Meningococcal
 Mumps
 Pertussis
 Pneumococcal
 Polio
 Rabies
 Rotavirus
 Rubella
 Shingles (zoster)
 Tetanus
HHS Anthrax Vaccine Advisors Weigh Pediatric Use
CIDRAP News - 9/22/11
A federal working group recommends that the US government assess the safety and immunogenicity of anthrax vaccine in children before an attack with Bacillus anthracis occurs rather than after, according to a presentation today before the National Biodefense Science Board (NBSB). Researchers are more familiar with the vaccine's safety and immunogencity in adults, because it has been used in about 2.5 million military members. However, no studies have been conducted in children, who make up 25% of the US population, though federal bioterror response plans call for both groups to receive three doses of the vaccine, alongside antibiotic prophylaxis, after an anthrax attack.
A Look Back at 9/11 in "I Heard The Sirens Scream"
NPR - 8/26/11
In a new book, "I Heard the Sirens Scream" Pulitzer Prize winner Laurie Garrett gives her account of the World Trade Center attacks ten years ago, and tells how she thinks those events, combined with the anthrax attacks that came shortly after, changed the country's course.
New Contract Shows Anthrax Threat Real
UPI - 9/20/10
A new multimillion-dollar government contract for a Maryland biological security research company indicates the threat of an anthrax outbreak as a result of bioterrorism remains a major priority for the Obama administration. Emergent BioSolutions Inc., which has headquarters in Rockville, Md., said it signed a contract valued at up to $186.6 million with the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services. The contract will enable the company to develop a recombinant protective antigen anthrax vaccine, which is likely to produce a more rapid response to anthrax infection than existing vaccines.
VIEW ALL:
2011
|
2010
|
2009
|
2008
 
 
Vaccine News
News & Information Home
View All
Vaccine Index
Topic Index
News & Information
IAC Express
Weekly email immunization news for health professionals
What's New at IAC
New and revised handouts and staff resources and VIS translations
Official Releases
Vaccine licensures, recommendations, and resources
Calendar of Events
Conferences and meetings on immunization
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 5U38IP000290) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.